BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Nguyen HB, Le XT, Nguyen HH, Vo TT, Le MK, Nguyen NT, Do-nguyen TM, Truong-nguyen CM, Nguyen BT. Diagnostic Value of hTERT mRNA and in Combination With AFP, AFP-L3%, Des-γ-carboxyprothrombin for Screening of Hepatocellular Carcinoma in Liver Cirrhosis Patients HBV or HCV-Related. Cancer Inform 2022;21:117693512211007. [DOI: 10.1177/11769351221100730] [Reference Citation Analysis]
2 Lv HC, Lv YY, Wang G, Zhang XH, Li SN, Yue XF, Lu W. Mechanism of miR-424-5p promoter methylation in promoting epithelial-mesenchymal transition of hepatocellular carcinoma cells. Kaohsiung J Med Sci 2022. [PMID: 35049148 DOI: 10.1002/kjm2.12499] [Reference Citation Analysis]
3 Moldogazieva NT, Zavadskiy SP, Terentiev AA. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine. Cancer Genomics Proteomics 2021;18:369-83. [PMID: 33994362 DOI: 10.21873/cgp.20266] [Reference Citation Analysis]
4 Xu J, Li S, Feng Y, Zhang J, Peng Y, Wang X, Wang H. The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery. CMAR 2022;Volume 14:1795-806. [DOI: 10.2147/cmar.s361462] [Reference Citation Analysis]
5 Yin F, Cao N, Xiang X, Feng H, Li F, Li M, Xia Q, Zuo X. DNA Framework-based Topological Aptamer for Differentiating Subtypes of Hepatocellular Carcinoma Cells. Chem Res Chin Univ 2021;37:919-24. [DOI: 10.1007/s40242-021-1159-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ding L, Yu Q, Yang S, Yang WJ, Liu T, Xian JR, Tian TT, Li T, Chen W, Wang BL, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma. Front Immunol 2022;13:831101. [PMID: 35371079 DOI: 10.3389/fimmu.2022.831101] [Reference Citation Analysis]
7 Salani F, Latarani M, Casadei-Gardini A, Gangadharannambiar P, Fornaro L, Vivaldi C, Pecora I, Massa V, Marisi G, Canale M, Ulivi P, Scartozzi M, Eccleston M, Masi G, Crea F. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics 2022. [PMID: 35473355 DOI: 10.2217/epi-2021-0383] [Reference Citation Analysis]
8 He L, Wang S, Ma X. The Influence of ICAM1 3'UTR Gene Polymorphism on the Occurrence and Metastasis of Primary Liver Cancer. Biomed Res Int 2021;2021:7377299. [PMID: 34869770 DOI: 10.1155/2021/7377299] [Reference Citation Analysis]
9 Chen S, Zhang Y, Ding X, Li W. Identification of lncRNA/circRNA-miRNA-mRNA ceRNA Network as Biomarkers for Hepatocellular Carcinoma. Front Genet 2022;13:838869. [PMID: 35386284 DOI: 10.3389/fgene.2022.838869] [Reference Citation Analysis]
10 Liu L, Liu B, Yu J, Zhang D, Shi J, Liang P. Development of a Toll-Like Receptor-Based Gene Signature That Can Predict Prognosis, Tumor Microenvironment, and Chemotherapy Response for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:729789. [PMID: 34621787 DOI: 10.3389/fmolb.2021.729789] [Reference Citation Analysis]
11 Fang C, Wang H, Lin Z, Liu X, Dong L, Jiang T, Tan Y, Ning Z, Ye Y, Tan G, Xu G. Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics. Cancers (Basel) 2022;14:231. [PMID: 35008393 DOI: 10.3390/cancers14010231] [Reference Citation Analysis]
12 Hou L, Zeng X, Li X, Zhao C, Zou J, Li Y, Liu G. MCM6 Promotes Hepatocellular Carcinoma Progression via the Notch Pathway: Clinical, Functional, and Genomic Insights. Comput Math Methods Med 2022;2022:3116303. [PMID: 35720029 DOI: 10.1155/2022/3116303] [Reference Citation Analysis]
13 Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020;9:E2382. [PMID: 33143149 DOI: 10.3390/cells9112382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142 [PMID: 34630880 DOI: 10.4254/wjh.v13.i9.1132] [Reference Citation Analysis]
15 Mu X, Zhong Y, Zhang X, Qu C, Chen S. Early Diagnosis Value of DCE-MRI Hemodynamic Parameters in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/9556589] [Reference Citation Analysis]
16 Shang H, Liu ZP. Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking. Comput Struct Biotechnol J 2022;20:206-17. [PMID: 35024093 DOI: 10.1016/j.csbj.2021.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sternby Eilard M, Åberg F. Combination of biomarkers for the detection of hepatocellular carcinoma. Ann Transl Med 2020;8:1283. [PMID: 33209863 DOI: 10.21037/atm-20-5798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 El-Nakeep S. Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises). World J Gastrointest Pathophysiol 2022; 13(1): 1-14 [PMID: 35116176 DOI: 10.4291/wjgp.v13.i1.1] [Reference Citation Analysis]
19 Li H, Li T, Zhang X. Identification of a Pyroptosis-Related Prognostic Signature Combined With Experiments in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:822503. [DOI: 10.3389/fmolb.2022.822503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ye M, Wang S, Qie JB, Sun PL. SPRY4-AS1, A Novel Enhancer RNA, Is a Potential Novel Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma. Front Oncol 2021;11:765484. [PMID: 34671565 DOI: 10.3389/fonc.2021.765484] [Reference Citation Analysis]
21 Li Y, Xiong H. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways. BMC Cancer 2022;22:298. [PMID: 35313850 DOI: 10.1186/s12885-022-09398-3] [Reference Citation Analysis]
22 Ying L, Cheng M, Lu Y, Tao Q, Chen X, Shen B, Xiong F, Hu Z, Wang D, Li X. Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma. Pathol Oncol Res 2021;27:1610075. [PMID: 34992505 DOI: 10.3389/pore.2021.1610075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Wan Z, Wang X. Role of SLC39A6 in the development and progression of liver cancer. Oncol Lett 2022;23:77. [PMID: 35111246 DOI: 10.3892/ol.2022.13197] [Reference Citation Analysis]
24 Zamora-León SP. Hepatocellular carcinoma biomarkers, an imminent need. World J Gastrointest Oncol 2021; 13(11): 1847-1849 [PMID: 34853655 DOI: 10.4251/wjgo.v13.i11.1847] [Reference Citation Analysis]
25 Hsiang CW, Huang WY, Yang JF, Shen PC, Dai YH, Wang YF, Lin CS, Chang WC, Lo CH. Dynamic Changes in Neutrophil-to-Lymphocyte Ratio are Associated with Survival and Liver Toxicity Following Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1299-309. [PMID: 34765571 DOI: 10.2147/JHC.S334933] [Reference Citation Analysis]
26 Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Bedon L, Dal Bo M, Mossenta M, Busato D, Toffoli G, Polano M. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. Int J Mol Sci 2021;22:1075. [PMID: 33499054 DOI: 10.3390/ijms22031075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Xu Y, Yu X, Sun Z, He Y, Guo W. Roles of lncRNAs Mediating Wnt/β-Catenin Signaling in HCC. Front Oncol 2022;12:831366. [PMID: 35356220 DOI: 10.3389/fonc.2022.831366] [Reference Citation Analysis]
29 Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol 2021;19:241. [PMID: 34389000 DOI: 10.1186/s12957-021-02354-8] [Reference Citation Analysis]
30 Yu Q, Chen W, Li Y, He J, Wang Y, Yang S, Zhou J. The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. Bioengineered 2022;13:4717-29. [PMID: 35212603 DOI: 10.1080/21655979.2022.2031398] [Reference Citation Analysis]
31 Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett 2021;21:487. [PMID: 33968203 DOI: 10.3892/ol.2021.12748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Cabiati M, Gaggini M, De Simone P, Del Ry S. Data mining of key genes expression in hepatocellular carcinoma: novel potential biomarkers of diagnosis prognosis or progression. Clin Exp Metastasis 2022. [PMID: 35429302 DOI: 10.1007/s10585-022-10164-9] [Reference Citation Analysis]
34 He Q, Fan B, Du P, Jin Y. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis. Front Cell Dev Biol 2022;10:806989. [DOI: 10.3389/fcell.2022.806989] [Reference Citation Analysis]
35 Zhang Y, Wang F, Wang Y. LncRNA TSPEAR-AS1 predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma and promotes metastasis via miR-1915-5p. Virus Res 2022;:198788. [PMID: 35477008 DOI: 10.1016/j.virusres.2022.198788] [Reference Citation Analysis]
36 Xu Y, Tian H, Luan CG, Sun K, Bao PJ, Zhang HY, Zhang N. Telocytes promote hepatocellular carcinoma by activating the ERK signaling pathway and miR-942-3p/MMP9 axis. Cell Death Discov 2021;7:209. [PMID: 34376644 DOI: 10.1038/s41420-021-00592-z] [Reference Citation Analysis]
37 Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, Dalekos GN. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers (Basel) 2021;13:3510. [PMID: 34298722 DOI: 10.3390/cancers13143510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Chen L, Yang Z, Cao Y, Hu Y, Bao W, Wu D, Hu L, Xie J, Yu H. Pan-cancer analysis and single-cell analysis revealed the role of ABCC5 transporter in hepatocellular carcinoma. Channels (Austin) 2021;15:541-54. [PMID: 34494510 DOI: 10.1080/19336950.2021.1968592] [Reference Citation Analysis]
39 Liu Y, Chen Y, Fei W, Zheng C, Zheng Y, Tang M, Qian Y, Zhang X, Zhao M, Zhang M, Wang F. Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic. Front Bioeng Biotechnol 2021;9:733792. [PMID: 34557478 DOI: 10.3389/fbioe.2021.733792] [Reference Citation Analysis]
40 Tohme S, Yazdani HO, Rahman A, Handu S, Khan S, Wilson T, Geller DA, Simmons RL, Molinari M, Kaltenmeier C. The Use of Machine Learning to Create a Risk Score to Predict Survival in Patients with Hepatocellular Carcinoma: A TCGA Cohort Analysis. Can J Gastroenterol Hepatol 2021;2021:5212953. [PMID: 34888264 DOI: 10.1155/2021/5212953] [Reference Citation Analysis]
41 Liu YM, Cao Y, Zhao PS, Wu LY, Lu YM, Wang YL, Zhao JF, Liu XG. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway. Int J Biol Sci 2022;18:637-51. [PMID: 35002514 DOI: 10.7150/ijbs.66915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wang L, Wu M, Li R, Xu X, Zhu C, Feng X. MVI-Mind: A Novel Deep-Learning Strategy Using Computed Tomography (CT)-Based Radiomics for End-to-End High Efficiency Prediction of Microvascular Invasion in Hepatocellular Carcinoma. Cancers (Basel) 2022;14:2956. [PMID: 35740620 DOI: 10.3390/cancers14122956] [Reference Citation Analysis]
43 Huang J, Kang W, Pan S, Yu C, Jie Z, Chen C, Ciccarone F. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/6891155] [Reference Citation Analysis]
44 Falahi S, Rafiee-Pour HA, Zarejousheghani M, Rahimi P, Joseph Y. Non-Coding RNA-Based Biosensors for Early Detection of Liver Cancer. Biomedicines 2021;9:964. [PMID: 34440168 DOI: 10.3390/biomedicines9080964] [Reference Citation Analysis]
45 Liu Y, Fu B, Yu Z, Song G, Zeng H, Gong Y, Ding Y, Huang D. Identification of KRBA1 as a Potential Prognostic Biomarker Associated with Immune Infiltration and m6A Modification in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:497-516. [PMID: 35669909 DOI: 10.2147/JHC.S363862] [Reference Citation Analysis]
46 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Wu D, Zhang R, Zhan L. Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile. Clin Res Hepatol Gastroenterol 2021;46:101812. [PMID: 34597849 DOI: 10.1016/j.clinre.2021.101812] [Reference Citation Analysis]
48 Qiu Y, Li H, Xie J, Qiao X, Wu J. Identification of ABCC5 Among ATP-Binding Cassette Transporter Family as a New Biomarker for Hepatocellular Carcinoma Based on Bioinformatics Analysis. Int J Gen Med 2021;14:7235-46. [PMID: 34737618 DOI: 10.2147/IJGM.S333904] [Reference Citation Analysis]
49 Hara Y, Yamamura K, Matsumura K, Oda E, Akahoshi S, Yuki H, Tomiguchi J, Motohara T, Miyamoto H, Komohara Y, Beppu T. Laparoscopic Surgery for a Patient With Multiple Liver Metastases of Unknown Origin Concomitant With Gallbladder Tumor. In Vivo 2021;35:2963-8. [PMID: 34410995 DOI: 10.21873/invivo.12590] [Reference Citation Analysis]